Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Patent
1996-04-17
1998-08-25
Kulkosky, Peter F.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
424630, 606151, 606152, 514 8, A61K 3334, A61K 970, A61L 2500, A61L 1500
Patent
active
057981167
DESCRIPTION:
BRIEF SUMMARY
This application claims benefit of international application PCT/GB94/01648, filed Jul. 29, 1994.
The present invention relates to stabilised materials for wound healing in humans and animals.
There are four stages which can usually be identified in the natural healing process. Initially the wound is closed so as to limit blood loss and prevent infection. Then damaged tissue is removed and pathogens destroyed by phagocytosis. This is followed by granulation in which the wound is invaded by cell types appropriate to the surrounding tissue and scar formation occurs. Finally the scar tissue is remodelled and changes in the cell population occur resulting in a mature, healed wound. In any particular case variations from this general pattern will occur owing to factors such as the site and type of wound and the condition of the patient. The details of the process, particularly the later stages are, as yet, not well understood.
Although very effective in most cases, the natural wound healing process can fail on occasion, or may be unsatisfactory, and medical intervention is desirable. Typical examples of failure include cases of severe burns involving substantial tissue damage where the wounds often do not even close completely and where skin grafts are required to secure granulation, cases of leg ulcers where, even when the wounds heal, the healed scar is physically weak and liable to break open very easily and cases where, although a wound would heal naturally, the scarring that remains may be unsightly or cause discomfort. Other wounds which frequently require intervention are serious bone fractures and wounds to cartilage, ligaments and tendons which heal slowly or not at all or where the healed wound will not be sufficiently strong.
Despite considerable work over many years there have been no completely satisfactory treatments for many of these problems in wound healing. One approach to improving wound healing is the administration of wound healing promoters such as growth factors. However, there are many difficulties with this, particularly in ensuring that the agents are delivered to the site of the wound in effective amounts.
WO-A-9 220 716 describes ferric hyaluronates, which are said to be antimicrobial agents and wound healing agents. They are also said to be useful as carriers for other therapeutically active substances such as TNF, insulin and interferon.
We have previously shown that cell adhesion proteins promote wound healing when applied to the wound and have developed macroscopically oriented materials (WO-A-92/13003), comprising a cell adhesion protein such as fibronectin, which promote wound healing, in particular by creating a scaffolding to which the invading cells can adhere thus facilitating this stage of the wound healing procedure. By aligning these materials with features of the wound or surrounding tissue, cell invasion may be directed along desired orientations thereby strengthening the initial repair and reducing the amount of reorientation required during the remodelling stage. Thus, wound healing may be promoted and the mature healed wound can be made stronger or more cosmetically acceptable or both.
We have also previously developed a depot composition for treatment of wounds comprising fibronectin or a fragment thereof, a growth factor binding agent linked thereto and a growth factor bound to the binding agent (WO-A-92/12739). The growth factor which promotes wound healing is concentrated on and released from an appropriate binding molecule itself immobilised on a material comprising a binding domain of fibronectin.
Copper is known to be important in tissue repair with roles in collagen synthesis (Siegel (1979) Int. Rev. Conn. Tiss. Res. 8, 79-118), free radical clearance (Dogan et al (1989) British Journal of Dermatology (1989) 120, 239-244) and angiogenesis (Brem et al (1990) American Journal of Pathology 137, (5), 1121; Brem et al (1990) Neurosurgery 26, (3), 391; McAuslan and Reilly (1980) Experimental Cell Research 130, 147-157). Copper depletion has been reported in severe
REFERENCES:
patent: 5443816 (1995-08-01), Zamora et al.
patent: 5554375 (1996-09-01), Pickart
Maquart, et al: "In Vivo Stimulation of Connective Tissue Accumulation by the Tripepetide-Copper Complex Glycyl-L-histidyl-L-Cu.sup.2+ in Rat Experimental Wounds", The Journal of Clinical Investigation, vol. 92, No. 5, Nov. 1993, pp. 2368-2376, see the whole docoument.
Kulkosky Peter F.
University College London
LandOfFree
Stabilized materials comprised of copper ion-containing fibronec does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized materials comprised of copper ion-containing fibronec, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized materials comprised of copper ion-containing fibronec will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-34587